POS0545 PRE-EXPOSURE PROPHYLAXIS OF COVID-19 WITH TIXAGEVIMAB AND CILGAVIMAB IN RHEUMATOLOGIC PATIENTS TREATED WITH RITUXIMAB: DATA FROM A SINGLE-CENTRE COHORT

Background Rheumatologic patients treated with Rituximab (RTX) are at higher risk of severe COVID-19 and death. The B-cell depletive treatment significantly affects B cell functions involved in anti-SARS-CoV-2 response, leading to relevant impacts on the clinical serological course infection, long-term immunity, vaccine responses. In light these observations, pre-exposure prophylaxis (PrEP) Tixagevimab Cilgavimab (TGM/CGM) was recently approved Italy for all RTX previous year, independently their status against SARS-CoV-2. Objectives We aimed evaluate efficacy safety TGM/CGM a single-centre cohort rheumatologic RTX. Methods From October 2022, who had been 12 months underwent assessment our tertiary centre were screened eligibility PrEP TGM/CGM. According indications Italian Medicines Agency (AIFA), we excluded subjects major cardiovascular factors and/or coagulation abnormalities; those reported allergic reaction any anti-COVID19 referred an allergologist evaluation before administration. Patients agreed be signed informed consent. Clinical demographic features collected baseline, follow-up phone performed day after 1 month administration, assess tolerability new COVID-19- related events. A descriptive analysis performed. Results 2022 31 December 90 Among them, 11 contraindications due comorbidities 55 refused receive COVID-19, 21 received 3 scheduled January2023. mean age 54 years (standard deviation: 17) 19 (90.5%) female; 9 affected by rheumatoid arthritis other diseases (3 systemic lupus erythematosus, 2 sclerosis, Sjögren syndrome, juvenile idiopathic arthritis, anti-synthetase vasculitides). Most them completed vaccination schedule (19, 90.5%) (42.8%) infectious event SARS-CoV-2 year. One no patient adverse events nor symptoms. Conclusion well tolerated population year symptoms observed Future observations may provide further data preventing COVID-19. REFERENCES: NIL. Acknowledgements: Disclosure Interests Maria Manara Speakers bureau: Novartis, Angelini, Consultant of: Lilly, MSD, Manuel Sette: None declared, Laura Giudice: Martina Biggioggero: Nicoletta Del Papa Janssen, Boehringer-Ingelheim, Actelion, Ennio Giulio Favalli AbbVie, BMS, Celltrion, Galapagos, Pfizer, UCB, Gerosa: Francesca Ingegnoli: Roberto Caporali Amgen, Fresenius, UCB.